Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
  • C07K1/14—Extraction; Separation; Purification
  • C07K1/16—Extraction; Separation; Purification by chromatography
  • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
  • G01N33/54326—Magnetic particles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
  • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
  • G01N33/54326—Magnetic particles
  • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56911—Bacteria
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
  • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
  • B01L2200/06—Fluid handling related problems
  • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
  • B01L2400/00—Moving or stopping fluids
  • B01L2400/04—Moving fluids with specific forces or mechanical means
  • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
  • B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
  • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2446/00—Magnetic particle immunoreagent carriers
  • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
  • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

• the invention generally relates to using magnetic particles and magnets to isolate a target analyte from a body fluid sample.
• Blood-borne pathogens are a significant healthcare problem.
• a delayed or improper diagnosis of a bacterial infection can result in sepsis—a serious, and often deadly, inflammatory response to the infection.
• Sepsis is the 10 th leading cause of death in the United States.
• Early detection of bacterial infections in blood is the key to preventing the onset of sepsis.
• Traditional methods of detection and identification of blood-borne infection include blood culture and antibiotic susceptibility assays. Those methods typically require culturing cells, which can be expensive and can take as long as 72 hours. Often, septic shock will occur before cell culture results can be obtained.
• the present invention provides methods and devices for isolating pathogens in a biological sample.
• the invention allows the rapid detection of pathogen at very low levels in the sample; thus enabling early and accurate detection and identification of the pathogen.
• the invention is carried out with magnetic particles having a target-specific binding moiety.
• Methods of the invention involve introducing magnetic particles including a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to a target, applying a magnetic field to capture target/magnetic particle complexes on a surface, and washing with a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes.
• a particular advantage of methods of the invention is for capture and isolation of bacteria and fungi directly from blood samples at low concentrations that are present in many clinical samples (as low as 1 CFU/ml of bacteria in a blood sample).
• the target-specific binding moiety will depend on the target to be captured.
• the moiety may be any capture moiety known in the art, such as an antibody, an aptamer, a nucleic acid, a protein, a receptor, a phage or a ligand.
• the target-specific binding moiety is an antibody.
• the antibody is specific for bacteria. In other embodiments, the antibody is specific for fungi.
• the target analyte refers to the target that will be captured and isolated by methods of the invention.
• the target may be bacteria, fungi, protein, a cell, a virus, a nucleic acid, a receptor, a ligand, or any molecule known in the art.
• the target is a pathogenic bacteria.
• the target is a gram positive or gram negative bacteria.
• Exemplary bacterial species that may be captured and isolated by methods of the invention include E.
• Magnetic particles generally fall into two broad categories.
• the first category includes particles that are permanently magnetizable, or ferromagnetic; and the second category includes particles that demonstrate bulk magnetic behavior only when subjected to a magnetic field.
• the latter are referred to as magnetically responsive particles.
• Materials displaying magnetically responsive behavior are sometimes described as superparamagnetic.
• materials exhibiting bulk ferromagnetic properties e.g., magnetic iron oxide, may be characterized as superparamagnetic when provided in crystals of about 30 nm or less in diameter. Larger crystals of ferromagnetic materials, by contrast, retain permanent magnet characteristics after exposure to a magnetic field and tend to aggregate thereafter due to strong particle-particle interaction.
• the particles are superparamagnetic beads. In other embodiments, the magnetic particles include at least 70% superparamagnetic beads by weight. In certain embodiments, the superparamagnetic beads are from about 100 nm to about 250 nm in diameter. In certain embodiments, the magnetic particle is an iron-containing magnetic particle. In other embodiments, the magnetic particle includes iron oxide or iron platinum.
• the incubating step includes incubating the mixture in a buffer that inhibits cell lysis.
• the buffer includes Tris(hydroximethyl)-aminomethane hydrochloride at a concentration of between about 50 mM and about 100 mM, preferably about 75 mM.
• methods of the invention further include retaining the magnetic particles in a magnetic field during the washing step. Methods of the invention may be used with any body fluid. Exemplary body fluids include blood, sputum, serum, plasma, urine, saliva, sweat, and cerebral spinal fluid.
• Another aspect of the invention provides methods for isolating a target microorganism from a body fluid sample including introducing magnetic particles having a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to the target, applying a magnetic field to isolate on a surface magnetic particles to which target is bound, washing the mixture in a wash solution that reduces particle aggregation, and lysing the captured bacteria and extracting DNA for further analysis by PCR, microarray hybridization or sequencing.
• Another aspect of the invention provides methods for isolating as low as 1 CFU/ml of bacteria in a blood sample including introducing superparamagnetic particles having a diameter from about 100 nm to about 250 nm and having a bacteria-specific binding moiety to a body fluid sample in order to create a mixture, incubating said mixture to allow said particles to bind to a bacteria, applying a magnetic field to isolate on a surface bacteria/magnetic particle complexes, and washing the mixture in a wash solution that reduces particle aggregation, thereby isolating as low as 1 viable CFU/ml of bacteria in the blood sample.
• the invention generally relates to using magnetic particles that capture target pathogens in a body fluid sample and magnets to isolate the target.
• Methods of the invention involve introducing magnetic particles including a target-specific binding moiety to a body fluid sample in order to create a mixture, incubating the mixture to allow the particles to bind to a target, applying a magnetic field to capture target/magnetic particle complexes on a surface, and washing the mixture in a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes.
• Certain fundamental technologies and principles are associated with binding magnetic materials to target entities and subsequently separating by use of magnet fields and gradients. Such fundamental technologies and principles are known in the art and have been previously described, such as those described in Janeway (Immunobiology, 6 th edition, Garland Science Publishing), the content of which is incorporated by reference herein in its entirety.
• Methods of the invention involve collecting a body fluid having a target analyte in a container, such as a blood collection tube (e.g., VACUTAINER, test tube specifically designed for venipuncture, commercially available from Becton, Dickinson and company).
• a solution is added that prevents or reduces aggregation of endogenous aggregating factors, such as heparin in the case of blood.
• a body fluid refers to a liquid material derived from, for example, a human or other mammal.
• body fluids include, but are not limited to, mucus, blood, plasma, serum, serum derivatives, bile, phlegm, saliva, sweat, amniotic fluid, mammary fluid, urine, sputum, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF.
• CSF cerebrospinal fluid
• a body fluid may also be a fine needle aspirate.
• a body fluid also may be media containing cells or biological material. In particular embodiments, the fluid is blood.
• the target analyte refers to the substance in the sample that will be captured and isolated by methods of the invention.
• the target may be bacteria, fungi, a protein, a cell (such as a cancer cell, a white blood cell a virally infected cell, or a fetal cell circulating in maternal circulation), a virus, a nucleic acid (e.g., DNA or RNA), a receptor, a ligand, a hormone, a drug, a chemical substance, or any molecule known in the art.
• the target is a pathogenic bacteria.
• the target is a gram positive or gram negative bacteria.
• Exemplary bacterial species that may be captured and isolated by methods of the invention include E. coli, Listeria, Clostridium, Mycobacterium, Shigella, Borrelia, Campylobacter, Bacillus, Salmonella, Staphylococcus, Enterococcus, Pneumococcus, Streptococcus , and a combination thereof.
• the sample is then mixed with magnetic particles including a target-specific binding moiety to generate a mixture that is allowed to incubate such that the particles bind to a target in the sample, such as a bacterium in a blood sample.
• the mixture is allowed to incubate for a sufficient time to allow for the particles to bind to the target analyte.
• the process of binding the magnetic particles to the target analytes associates a magnetic moment with the target analytes, and thus allows the target analytes to be manipulated through forces generated by magnetic fields upon the attached magnetic moment.
• incubation time will depend on the desired degree of binding between the target analyte and the magnetic beads (e.g., the amount of moment that would be desirably attached to the target), the amount of moment per target, the amount of time of mixing, the type of mixing, the reagents present to promote the binding and the binding chemistry system that is being employed. Incubation time can be anywhere from about 5 seconds to a few days. Exemplary incubation times range from about 10 seconds to about 2 hours. Binding occurs over a wide range of temperatures, generally between 15 ° C. and 40 ° C.
• Methods of the invention may be performed with any type of magnetic particle.
• Production of magnetic particles and particles for use with the invention are known in the art. See for example Giaever (U.S. Pat. No. 3,970,518), Senyi et al. (U.S. Pat. No. 4,230,685), Dodin et al. (U.S. 4,677,055), Whitehead et al. (U.S. Pat. No. 4,695,393), Benjamin et al. (U.S. Pat. No. 5,695,946), Giaever (U.S. 4,018,886), Rembaum (U.S. Pat. No. 4,267,234), Molday (U.S. Pat. No.
• Magnetic particles generally fall into two broad categories.
• the first category includes particles that are permanently magnetizable, or ferromagnetic; and the second category includes particles that demonstrate bulk magnetic behavior only when subjected to a magnetic field.
• the latter are referred to as magnetically responsive particles.
• Materials displaying magnetically responsive behavior are sometimes described as superparamagnetic.
• materials exhibiting bulk ferromagnetic properties e.g., magnetic iron oxide, may be characterized as superparamagnetic when provided in crystals of about 30 nm or less in diameter. Larger crystals of ferromagnetic materials, by contrast, retain permanent magnet characteristics after exposure to a magnetic field and tend to aggregate thereafter due to strong particle-particle interaction.
• the particles are superparamagnetic beads.
• the magnetic particle is an iron containing magnetic particle.
• the magnetic particle includes iron oxide or iron platinum.
• the magnetic particles include at least about 10% superparamagnetic beads by weight, at least about 20% superparamagnetic beads by weight, at least about 30% superparamagnetic beads by weight, at least about 40% superparamagnetic beads by weight, at least about 50% superparamagnetic beads by weight, at least about 60% superparamagnetic beads by weight, at least about 70% superparamagnetic beads by weight, at least about 80% superparamagnetic beads by weight, at least about 90% superparamagnetic beads by weight, at least about 95% superparamagnetic beads by weight, or at least about 99% superparamagnetic beads by weight.
• the magnetic particles include at least about 70% superparamagnetic beads by weight.
• the superparamagnetic beads are less than 100 nm in diameter. In other embodiments, the superparamagnetic beads are about 150 nm in diameter, are about 200 nm in diameter, are about 250 nm in diameter, are about 300 nm in diameter, are about 350 nm in diameter, are about 400 nm in diameter, are about 500 nm in diameter, or are about 1000 nm in diameter. In a particular embodiment, the superparamagnetic beads are from about 100 nm to about 250 nm in diameter.
• the particles are beads (e.g., nanoparticles) that incorporate magnetic materials, or magnetic materials that have been functionalized, or other configurations as are known in the art.
• nanoparticles may be used that include a polymer material that incorporates magnetic material(s), such as nanometal material(s).
• those nanometal material(s) or crystal(s), such as Fe 3 O 4 are superparamagnetic, they may provide advantageous properties, such as being capable of being magnetized by an external magnetic field, and demagnetized when the external magnetic field has been removed. This may be advantageous for facilitating sample transport into and away from an area where the sample is being processed without undue bead aggregation.
• One or more or many different nanometal(s) may be employed, such as Fe 3 O 4 , FePt, or Fe, in a core-shell configuration to provide stability, and/or various others as may be known in the art.
• a certain saturation field may be provided. For example, for Fe 3 O 4 superparamagnetic particles, this field may be on the order of about 0.3 T.
• the size of the nanometal containing bead may be optimized for a particular application, for example, maximizing moment loaded upon a target, maximizing the number of beads on a target with an acceptable detectability, maximizing desired force-induced motion, and/or maximizing the difference in attached moment between the labeled target and non-specifically bound targets or bead aggregates or individual beads. While maximizing is referenced by example above, other optimizations or alterations are contemplated, such as minimizing or otherwise desirably affecting conditions.
• a polymer bead containing 80 wt % Fe 3 O 4 superparamagnetic particles, or for example, 90 wt % or higher superparamagnetic particles is produced by encapsulating superparamagnetic particles with a polymer coating to produce a bead having a diameter of about 250 nm.
• Magnetic particles for use with methods of the invention have a target-specific binding moiety that allows for the particles to specifically bind the target of interest in the sample.
• the target-specific moiety may be any molecule known in the art and will depend on the target to be captured and isolated.
• Exemplary target-specific binding moieties include nucleic acids, proteins, ligands, antibodies, aptamers, and receptors.
• the target-specific binding moiety is an antibody, such as an antibody that binds a particular bacterium.
• antibody production including criteria to be considered when choosing an animal for the production of antisera, are described in Harlow et al. (Antibodies, Cold Spring Harbor Laboratory, pp. 93-117, 1988).
• an animal of suitable size such as goats, dogs, sheep, mice, or camels are immunized by administration of an amount of immunogen, such the target bacteria, effective to produce an immune response.
• An exemplary protocol is as follows.
• the animal is injected with 100 milligrams of antigen resuspended in adjuvant, for example Freund's complete adjuvant, dependent on the size of the animal, followed three weeks later with a subcutaneous injection of 100 micrograms to 100 milligrams of immunogen with adjuvant dependent on the size of the animal, for example Freund's incomplete adjuvant. Additional subcutaneous or intraperitoneal injections every two weeks with adjuvant, for example Freund's incomplete adjuvant, are administered until a suitable titer of antibody in the animal's blood is achieved.
• Exemplary titers include a titer of at least about 1:5000 or a titer of 1:100,000 or more, i.e., the dilution having a detectable activity.
• the antibodies are purified, for example, by affinity purification on columns containing protein G resin or target-specific affinity resin.
• Immunomagnetic beads against Salmonella are provided in Vermunt et al. (J. Appl. Bact. 72:112, 1992). Immunomagnetic beads against Staphylococcus aureus are provided in Johne et al. (J. Clin. Microbiol. 27:1631, 1989). Immunomagnetic beads against Listeria are provided in Skjerve et al. (Appl. Env. Microbiol. 56:3478, 1990). Immunomagnetic beads against Escherichia coli are provided in Lund et al. (J. Clin. Microbiol. 29:2259, 1991).
• a buffer solution is added to the sample along with the magnetic beads.
• An exemplary buffer includes Tris(hydroximethyl)-aminomethane hydrochloride at a concentration of about 75 mM. It has been found that the buffer composition, mixing parameters (speed, type of mixing, such as rotation, shaking etc., and temperature) influence binding. It is important to maintain osmolality of the final solution (e.g., blood+buffer) to maintain high label efficiency.
• buffers used in methods of the invention are designed to prevent lysis of blood cells, facilitate efficient binding of targets with magnetic beads and to reduce formation of bead aggregates. It has been found that the buffer solution containing 300 mM NaCl, 75 mM Tris-HCl pH 8.0 and 0.1% Tween 20 meets these design goals.
• Tris(hydroximethyl)-aminomethane hydrochloride is a well established buffer compound frequently used in biology to maintain pH of a solution. It has been found that 75 mM concentration is beneficial and sufficient for high binding efficiency.
• Tween 20 is widely used as a mild detergent to decrease nonspecific attachment due to hydrophobic interactions.
• Various assays use Tween 20 at concentrations ranging from 0.01% to 1%. The 0.1% concentration appears to be optimal for the efficient labeling of bacteria, while maintaining blood cells intact.
• An alternative approach to achieve high binding efficiency while reducing time required for the binding step is to use static mixer, or other mixing devices that provide efficient mixing of viscous samples at high flow rates, such as at or around 5 mL/min.
• the sample is mixed with binding buffer in ratio of, or about, 1:1, using a mixing interface connector.
• the diluted sample then flows through a mixing interface connector where it is mixed with target-specific nanoparticles.
• Additional mixing interface connectors providing mixing of sample and antigen-specific nanoparticles can be attached downstream to improve binding efficiency.
• the combined flow rate of the labeled sample is selected such that it is compatible with downstream processing.
• a magnetic field is applied to the mixture to capture the complexes on a surface.
• Components of the mixture that are not bound to magnetic particles will not be affected by the magnetic field and will remain free in the mixture.
• Methods and apparatuses for separating target/magnetic particle complexes from other components of a mixture are known in the art. For example, a steel mesh may be coupled to a magnet, a linear channel or channels may be configured with adjacent magnets, or quadrapole magnets with annular flow may be used. Other methods and apparatuses for separating target/magnetic particle complexes from other components of a mixture are shown in Rao et al.
• the magnetic capture is achieved at high efficiency by utilizing a flow-through capture cell with a number of strong rare earth bar magnets placed perpendicular to the flow of the sample.
• the flow rate could be as high as 5 mL/min or more, while achieving capture efficiency close to 100%.
• Non-specific target entities may for example be bound at a much lower efficiency, for example 1% of the surface area, while a target of interest might be loaded at 50% or nearly 100% of the available surface area or available antigenic cites. However, even 1% loading may be sufficient to impart force necessary for trapping in a magnetic gradient flow cell or sample chamber.
• the sample may include: bound targets at a concentration of about 1/mL or a concentration less than about 10 6 /mL; background particles at a concentration of about 10 7 /ml to about 10 10 /ml; and non-specific targets at a concentration of about 10/ml to about 10 5 /ml.
• methods of the invention involve washing the surface with a wash solution that reduces particle aggregation, thereby isolating target/magnetic particle complexes from the magnetic particles that are not bound to target analytes and non-specific target entities.
• the wash solution minimizes the formation of the aggregates.
• Methods of the invention may use any wash solution that imparts a net negative charge to the magnetic particle that is not sufficient to disrupt interaction between the target-specific moiety of the magnetic particle and the target analyte. Without being limited by any particular theory or mechanism of action, it is believed that attachment of the negatively charged molecules in the wash solution to magnetic particles provides net negative charge to the particles and facilitates dispersal of non-specifically aggregated particles. At the same time, the net negative charge is not sufficient to disrupt strong interaction between the target-specific moiety of the magnetic particle and the target analyte (e.g., an antibody-antigen interaction).
• Exemplary solutions include heparin, Tris-HCl, Tris-borate-EDTA (TBE), Tris-acetate-EDTA (TAE), Tris-cacodylate, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid), PBS (phosphate buffered saline), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid), MES (2-N-morpholino)ethanesulfonic acid), Tricine (N-(Tri(hydroximethyl)methyl)glycine), and similar buffering agents.
• HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
• PBS phosphate buffered saline
• PIPES piperazine-N,N′-bis(2-ethanesulfonic acid
• MES 2-N-morpholino)ethanesulfonic acid
• Tricine N-(Tri(hydroximethyl)methyl)g
• the wash solution includes heparin.
• the heparin also reduces probability of clotting of blood components after magnetic capture.
• the bound targets are washed with heparin-containing buffer 1-3 times to remove blood components and to reduce formation of aggregates.
• the target may be analyzed by a multitude of existing technologies, such as miniature NMR , Polymerase Chain Reaction (PCR), mass spectrometry, fluorescent labeling and visualization using microscopic observation, fluorescent in situ hybridization (FISH), growth-based antibiotic sensitivity tests, and variety of other methods that may be conducted with purified target without significant contamination from other sample components.
• isolated bacteria are lysed with a chaotropic solution, and DNA is bound to DNA extraction resin. After washing of the resin, the bacterial DNA is eluted and used in quantitative RT-PCR to detect the presence of a specific species, and/or, subclasses of bacteria.
• captured bacteria is removed from the magnetic particles to which they are bound and the processed sample is mixed with fluorescent labeled antibodies specific to the bacteria or fluorescent Gram stain. After incubation, the reaction mixture is filtered through 0.2 ⁇ m to 1.0 ⁇ m filter to capture labeled bacteria while allowing majority of free beads and fluorescent labels to pass through the filter. Bacteria is visualized on the filter using microscopic techniques, e.g. direct microscopic observation, laser scanning or other automated methods of image capture. The presence of bacteria is detected through image analysis. After the positive detection by visual techniques, the bacteria can be further characterized using PCR or genomic methods.
• Detection of bacteria of interest can be performed by use of nucleic acid probes following procedures which are known in the art. Suitable procedures for detection of bacteria using nucleic acid probes are described, for example, in Stackebrandt et al. (U.S. Pat. No. 5,089,386), King et al. (WO 90/08841), Foster et al. (WO 92/15883), and Cossart et al. (WO 89/06699), each of which is hereby incorporated by reference.
• a suitable nucleic acid probe assay generally includes sample treatment and lysis, hybridization with selected probe(s), hybrid capture, and detection. Lysis of the bacteria is necessary to release the nucleic acid for the probes.
• the nucleic acid target molecules are released by treatment with any of a number of lysis agents, including alkali (such as NaOH), guanidine salts (such as guanidine thiocyanate), enzymes (such as lysozyme, mutanolysin and proteinase K), and detergents. Lysis of the bacteria, therefore, releases both DNA and RNA, particularly ribosomal RNA and chromosomal DNA both of which can be utilized as the target molecules with appropriate selection of a suitable probe.
• rRNA as the target molecule(s), may be advantageous because rRNAs constitute a significant component of cellular mass, thereby providing an abundance of target molecules.
• the use of rRNA probes also enhances specificity for the bacteria of interest, that is, positive detection without undesirable cross-reactivity which can lead to false positives or false detection.
• Hybridization includes addition of the specific nucleic acid probes.
• hybridization is the procedure by which two partially or completely complementary nucleic acids are combined, under defined reaction conditions, in an anti-parallel fashion to form specific and stable hydrogen bonds.
• the selection or stringency of the hybridization/reaction conditions is defined by the length and base composition of the probe/target duplex, as well as by the level and geometry of mis-pairing between the two nucleic acid strands. Stringency is also governed by such reaction parameters as temperature, types and concentrations of denaturing agents present and the type and concentration of ionic species present in the hybridization solution.
• the hybridization phase of the nucleic acid probe assay is performed with a single selected probe or with a combination of two, three or more probes. Probes are selected having sequences which are homologous to unique nucleic acid sequences of the target organism.
• a first capture probe is utilized to capture formed hybrid molecules.
• the hybrid molecule is then detected by use of antibody reaction or by use of a second detector probe which may be labelled with a radioisotope (such as phosphorus-32) or a fluorescent label (such as fluorescein) or chemiluminescent label.
• Detection of bacteria of interest can also be performed by use of PCR techniques.
• a suitable PCR technique is described, for example, in Verhoef et al. (WO 92/08805). Such protocols may be applied directly to the bacteria captured on the magnetic beads. The bacteria is combined with a lysis buffer and collected nucleic acid target molecules are then utilized as the template for the PCR reaction.
• isolated bacteria are contacted with antibodies specific to the bacteria of interest.
• antibodies specific to the bacteria of interest either polyclonal or monoclonal antibodies can be utilized, but in either case have affinity for the particular bacteria to be detected. These antibodies, will adhere/bind to material from the specific target bacteria.
• labeling of the antibodies these are labeled either directly or indirectly with labels used in other known immunoassays.
• Direct labels may include fluorescent, chemiluminescent, bioluminescent, radioactive, metallic, biotin or enzymatic molecules. Methods of combining these labels to antibodies or other macromolecules are well known to those in the art. Examples include the methods of Hijmans, W. et al. (1969), Clin. Exp. Immunol.
• detector antibodies may also be labeled indirectly.
• the actual detection molecule is attached to a secondary antibody or other molecule with binding affinity for the anti-bacteria cell surface antibody.
• a secondary antibody is used it is preferably a general antibody to a class of antibody (IgG and IgM) from the animal species used to raise the anti-bacteria cell surface antibodies.
• the second antibody may be conjugated to an enzyme, either alkaline phosphatase or to peroxidase.
• the isolated component of the sample is immersed in a solution containing a chromogenic substrate for either alkaline phosphatase or peroxidase.
• a chromogenic substrate is a compound that can be cleaved by an enzyme to result in the production of some type of detectable signal which only appears when the substrate is cleaved from the base molecule.
• the chromogenic substrate is colorless, until it reacts with the enzyme, at which time an intensely colored product is made. Thus, material from the bacteria colonies adhered to the membrane sheet will become an intense blue/purple/black color, or brown/red while material from other colonies will remain colorless.
• detection molecules include fluorescent substances, such as 4-methylumbelliferyl phosphate, and chromogenic substances, such as 4-nitrophenylphosphate, 3,3′,5,5′-tetramethylbenzidine and 2,2′-azino-di-[3-ethelbenz-thiazoliane sulfonate (6)].
• fluorescent substances such as 4-methylumbelliferyl phosphate
• chromogenic substances such as 4-nitrophenylphosphate, 3,3′,5,5′-tetramethylbenzidine and 2,2′-azino-di-[3-ethelbenz-thiazoliane sulfonate (6)].
• other useful enzymes include ⁇ -galactosidase, ⁇ -glucuronidase, ⁇ -glucosidase, ⁇ -glucosidase, ⁇ -mannosidase, galactose oxidase, glucose oxidase and hexokinase.
• Detection of bacteria of interest using NMR may be accomplished as follows.
• the target of interest such as a magnetically labeled bacterium
• the target of interest may be delivered by a fluid medium, such as a fluid substantially composed of water.
• the magnetically labeled target may go from a region of very low magnetic field to a region of high magnetic field, for example, a field produced by an about 1 to about 2 Tesla magnet.
• the sample may traverse a magnetic gradient, on the way into the magnet and on the way out of the magnet.
• the target may experience a force pulling into the magnet in the direction of sample flow on the way into the magnet, and a force into the magnet in the opposite direction of flow on the way out of the magnet.
• the target may experience a retaining force trapping the target in the magnet if flow is not sufficient to overcome the gradient force.
• n is the viscosity
• r is the bead diameter
• F is the vector force
• B is the vector field
• m is the vector moment of the bead
• Magnetic fields on a path into a magnet may be non-uniform in the transverse direction with respect to the flow into the magnet.
• the time it takes a target to reach the wall of a conduit is associated with the terminal velocity and is lower with increasing viscosity.
• the terminal velocity is associated with the drag force, which may be indicative of creep flow in certain cases.
• Newtonian fluids have a flow characteristic in a conduit, such as a round pipe, for example, that is parabolic, such that the flow velocity is zero at the wall, and maximal at the center, and having a parabolic characteristic with radius.
• the velocity decreases in a direction toward the walls, and it is easier to magnetically trap targets near the walls, either with transverse gradients force on the target toward the conduit wall, or in longitudinal gradients sufficient to prevent target flow in the pipe at any position.
• the detection may be based on a perturbation of the NMR water signal caused by a magnetically labeled target (Sillerud et al., JMR (Journal of Magnetic Resonance), vol. 181, 2006).
• the sample may be excited at time 0 , and after some delay, such as about 50 ms or about 100 ms, an acceptable measurement (based on a detected NMR signal) may be produced.
• an acceptable measurement may be produced immediately after excitation, with the detection continuing for some duration, such as about 50 ms or about 100 ms. It may be advantageous to detect the NMR signal for substantially longer time durations after the excitation.
• the detection of the NMR signal may continue for a period of about 2 seconds in order to record spectral information at high-resolution.
• the perturbation excited at time 0 is typically smeared because the water around the perturbation source travels at different velocity, depending on radial position in the conduit.
• spectral information may be lost due to the smearing or mixing effects of the differential motion of the sample fluid during signal detection.
• Differential motion within a flowing Newtonian fluid may have deleterious effects in certain situations, such as a situation in which spatially localized NMR detection is desired, as in magnetic resonance imaging.
• a magnetic object such as a magnetically labeled bacterium
• the detection may be possible due to the magnetic field of the magnetic object, since this field perturbs the magnetic field of the fluid in the vicinity of the magnetic object.
• the detection of the magnetic object is improved if the fluid near the object remains near the object. Under these conditions, the magnetic perturbation may be allowed to act longer on any given volume element of the fluid, and the volume elements of the fluid so affected will remain in close spatial proximity. Such a stronger, more localized magnetic perturbation will be more readily detected using NMR or MRI techniques.
• the velocity of the fluid volume elements will depend on radial position in the fluid conduit.
• the fluid near a magnetic object will not remain near the magnetic object as the object flows through the detector.
• the effect of the magnetic perturbation of the object on the surrounding fluid may be smeared out in space, and the strength of the perturbation on any one fluid volume element may be reduced because that element does not stay within range of the perturbation.
• the weaker, less-well-localized perturbation in the sample fluid may be undetectable using NMR or MRI techniques.
• Certain liquids, or mixtures of liquids exhibit non-parabolic flow profiles in circular conduits. Such fluids may exhibit non-Newtonian flow profiles in other conduit shapes.
• the use of such a fluid may prove advantageous as the detection fluid in an application employing an NMR-based detection device. Any such advantageous effect may be attributable to high viscosity of the fluid, a plug-like flow profile associated with the fluid, and/or other characteristic(s) attributed to the fluid that facilitate detection.
• a shear-thinning fluid of high viscosity may exhibit a flow velocity profile that is substantially uniform across the central regions of the conduit cross-section. The velocity profile of such a fluid may transition to a zero or very low value near or at the walls of the conduit, and this transition region may be confined to a very thin layer near the wall.
• a mixture of glycerol and water can provide high viscosity, but the NMR measurement is degraded because separate NMR signals are detected from the water and glycerol molecules making up the mixture. This can undermine the sensitivity of the NMR detector.
• the non-water component of the fluid mixture can be chosen to have no NMR signal, which may be achieved by using a perdeuterated fluid component, for example, or using a perfluorinated fluid component. This approach may suffer from the loss of signal intensity since a portion of the fluid in the detection coil does not produce a signal.
• Another approach may be to use a secondary fluid component that constitutes only a small fraction of the total fluid mixture.
• a low-concentration secondary fluid component can produce an NMR signal that is of negligible intensity when compared to the signal from the main component of the fluid, which may be water.
• a perfluorinated or perdeuterated secondary fluid component may be used.
• the fluid mixture used in the NMR detector may include one, two, or more than two secondary components in addition to the main fluid component.
• the fluid components employed may act in concert to produce the desired fluid flow characteristics, such as high-viscosity and/or plug flow.
• the fluid components may be useful for providing fluid characteristics that are advantageous for the performance of the NMR detector, for example by providing NMR relaxation times that allow faster operation or higher signal intensities.
• a non-Newtonian fluid may provide additional advantages for the detection of objects by NMR or MRI techniques.
• the objects being detected may all have substantially the same velocity as they go through the detection coil. This characteristic velocity may allow simpler or more robust algorithms for the analysis of the detection data.
• the objects being detected may have fixed, known, and uniform velocity. This may prove advantageous in devices where the position of the detected object at later times is needed, such as in a device that has a sequestration chamber or secondary detection chamber down-stream from the NMR or MRI detection coil, for example.
• sample delivery into and out of a 1.7 T cylindrical magnet using a fluid delivery medium containing 0.1% to 0.5% Xanthan gum in water was successfully achieved.
• a fluid delivery medium containing 0.1% to 0.5% Xanthan gum in water is suitable to provide substantially plug-like flow, high viscosity, such as from about 10 cP to about 3000 cP, and good NMR contrast in relation to water.
• Xanthan gum acts as a non-Newtonian fluid, having characteristics of a non-Newtonian fluid that are well know in the art, and does not compromise NMR signal characteristics desirable for good detection in a desirable mode of operation.
• methods of the invention are useful for direct detection of bacteria from blood. Such a process is described here.
• Sample is collected in sodium heparin tube by venipuncture, acceptable sample volume is about 1 mL to 10 mL.
• Sample is diluted with binding buffer and superparamagnetic particles having target-specific binding moieties are added to the sample, followed by incubation on a shaking incubator at 37° C. for about 30 min to 120 min.
• Alternative mixing methods can also be used.
• sample is pumped through a static mixer, such that reaction buffer and magnetic beads are added to the sample as the sample is pumped through the mixer. This process allows for efficient integration of all components into a single fluidic part, avoids moving parts and separate incubation vessels and reduces incubation time.
• Capture of the labeled targets allows for the removal of blood components and reduction of sample volume from 30 mL to 5 mL.
• the capture is performed in a variety of magnet/flow configurations.
• methods include capture in a sample tube on a shaking platform or capture in a flow-through device at flow rate of 5 mL/min, resulting in total capture time of 6 min.
• wash buffer including heparin to remove blood components and free beads.
• the composition of the wash buffer is optimized to reduce aggregation of free beads, while maintaining the integrity of the bead/target complexes.
• the detection method is based on a miniature NMR detector tuned to the magnetic resonance of water.
• the NMR signal from water is clearly detectable and strong.
• the presence of magnetic material in the detector coil disturbs the magnetic field, resulting in reduction in water signal.
• One of the primary benefits of this detection method is that there is no magnetic background in biological samples which significantly reduces the requirements for stringency of sample processing.
• the detected signal is generated by water, there is a built-in signal amplification which allows for the detection of a single labeled bacterium.
• This method provides for isolation and detection of as low as or even lower than 1 CFU/ml of bacteria in a blood sample.
• Methods of the invention may also be combined with other separation and isolation protocols known in the art. Particularly, methods of the invention may be combined with methods shown in co-pending and co-owned U.S. Pat. No. patent application Ser. No. ______, filed ______, entitled Separating Target Analytes Using Alternating Magnetic Fields, and having Attorney Docket No.: NANO-002/00U.S. Pat No. 2,8864/4, the content of which is incorporated by reference herein in its entirety.
• Blood samples from healthy volunteers were spiked with clinically relevant concentrations of bacteria (1-10 CFU/mL) including both laboratory strains and clinical isolates of the bacterial species most frequently found in bloodstream infections.
• the immune serum was purified using affinity chromatography on a protein G sepharose column (GE Healthcare), and reactivity was determined using ELISA.
• Antibodies cross-reacting with Gram-negative bacteria and fungi were removed by absorption of purified IgG with formalin-fixed Gram-negative bacteria and fungi.
• the formalin-fixed organisms were prepared similar to as described above and mixed with IgG. After incubation for 2 hrs at room temperature, the preparation was centrifuged to remove bacteria. Final antibody preparation was clarified by centrifugation and used for the preparation of antigen-specific magnetic beads.
• Superparamagnetic beads were synthesized by encapsulating iron oxide nanoparticles (5-15 nm diameter) in a latex core and labeling with goat IgG.
• Ferrofluid containing nanoparticles in organic solvent was precipitated with ethanol, nanoparticles were resuspended in aqueous solution of styrene and surfactant Hitenol BC-10, and emulsified using sonication.
• the mixture was allowed to equilibrate overnight with stirring and filtered through 1.2 and 0.45 ⁇ m filters to achieve uniform micelle size.
• Styrene, acrylic acid and divynilbenzene were added in carbonate buffer at pH 9.6.
• the polymerization was initiated in a mixture at 70° C. with the addition of K2S2O8 and the reaction was allowed to complete overnight.
• the synthesized particles were washed 3 times with 0.1% SDS using magnetic capture, filtered through 1.2, 0.8, and 0.45 ⁇ m filters and used for antibody
• the production of beads resulted in a distribution of sizes that may be characterized by an average size and a standard deviation.
• the average size for optimal performance was found to be between 100 and 350 nm, for example between 200 nm to 250 nm.
• the purified IgG were conjugated to prepared beads using standard chemistry. After conjugation, the beads were resuspended in 0.1% BSA which is used to block non-specific binding sites on the bead and to increase the stability of bead preparation.
• the spiked samples as described in Example 1 were diluted 3-fold with a Tris-based binding buffer and target-specific beads, followed by incubation on a shaking platform at 37° C. for up to 2 hr. After incubation, the labeled targets were magnetically separated followed by a wash step designed to remove blood products. See example 5 below.
• Blood including the magnetically labeled target bacteria and excess free beads were injected into a flow-through capture cell with a number of strong rare earth bar magnets placed perpendicular to the flow of the sample.
• a flow rate as high as 5 mL/min was achieved.
• a wash solution including heparin was flowed through the channel.
• the bound targets were washed with heparin-containing buffer one time to remove blood components and to reduce formation of magnetic particle aggregates.
• the magnet was removed and captured magnetic material was resuspended in wash buffer, followed by re-application of the magnetic field and capture of the magnetic material in the same flow-through capture cell.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Biochemistry (AREA)
• Analytical Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Cell Biology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Food Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biophysics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Engineering & Computer Science (AREA)
• Virology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Apparatus Associated With Microorganisms And Enzymes (AREA)
• Dispersion Chemistry (AREA)
• Fluid Mechanics (AREA)
• Clinical Laboratory Science (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Sampling And Sample Adjustment (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Crystallography & Structural Chemistry (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=44816109

Family Applications (11)

Family Applications After (10)

Country Status (6)

Cited By (13)

Families Citing this family (31)

Citations (8)

Family Cites Families (298)

• 2010
  • 2010-08-04 US US12/850,203 patent/US20110262989A1/en not_active Abandoned
  • 2010-08-12 US US12/855,147 patent/US9389225B2/en active Active
• 2011
  • 2011-04-20 WO PCT/US2011/033184 patent/WO2011133630A1/en active Application Filing
  • 2011-04-20 CA CA2796897A patent/CA2796897C/en active Active
  • 2011-04-20 ES ES16190239T patent/ES2774393T3/es active Active
  • 2011-04-20 JP JP2013506262A patent/JP5814344B2/ja active Active
  • 2011-04-20 EP EP11772606.7A patent/EP2561360B9/en active Active
  • 2011-04-20 EP EP11772608.3A patent/EP2561099B1/en active Active
  • 2011-04-20 WO PCT/US2011/033186 patent/WO2011133632A1/en active Application Filing
  • 2011-04-20 ES ES11772606.7T patent/ES2656965T3/es active Active
  • 2011-04-20 EP EP16190239.0A patent/EP3138927B1/en active Active
  • 2011-04-20 CA CA2796767A patent/CA2796767C/en active Active
  • 2011-04-21 US US13/091,518 patent/US20110262932A1/en not_active Abandoned
  • 2011-04-21 ES ES11772698.4T patent/ES2685471T3/es active Active
  • 2011-04-21 EP EP11772698.4A patent/EP2561354B1/en active Active
  • 2011-04-21 WO PCT/US2011/033411 patent/WO2011133760A1/en active Application Filing
  • 2011-04-21 EP EP11772699.2A patent/EP2561361A4/en not_active Ceased
  • 2011-04-21 WO PCT/US2011/033410 patent/WO2011133759A1/en active Application Filing
  • 2011-04-21 US US13/091,534 patent/US9562896B2/en active Active
  • 2011-04-21 JP JP2013506301A patent/JP6023698B2/ja active Active
  • 2011-04-21 CA CA2796912A patent/CA2796912A1/en not_active Abandoned
  • 2011-04-21 CA CA2796900A patent/CA2796900C/en active Active
  • 2011-04-21 US US13/091,527 patent/US20110262933A1/en not_active Abandoned
  • 2011-04-21 US US13/091,548 patent/US9671395B2/en active Active
• 2016
  • 2016-07-11 US US15/206,751 patent/US11073513B2/en active Active
  • 2016-10-07 JP JP2016198681A patent/JP2017012198A/ja active Pending
• 2017
  • 2017-02-06 US US15/425,539 patent/US20170145406A1/en not_active Abandoned
  • 2017-04-25 US US15/496,790 patent/US9869671B2/en active Active
• 2018
  • 2018-01-10 US US15/866,628 patent/US10677789B2/en active Active
  • 2018-01-12 US US15/869,146 patent/US11448646B2/en active Active

Patent Citations (8)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events